Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Dirk Garmann"'
Autor:
Gustaf J. Wellhagen, Ashraf Yassen, Dirk Garmann, Astrid Bröker, Alexander Solms, Yang Zhang, Maria C. Kjellsson, Mats O. Karlsson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 5, Pp 812-822 (2024)
Abstract Item response theory (IRT) models are usually the best way to analyze composite or rating scale data. Standard methods to evaluate covariate or treatment effects in IRT models do not allow to identify item‐specific effects. Finding subgrou
Externí odkaz:
https://doaj.org/article/0139e12916414106b4d7f91451e70005
Autor:
Gustaf J. Wellhagen, Mats O. Karlsson, Maria C. Kjellsson, Dirk Garmann, Astrid Bröker, Yang Zhang, Mika Nokela, Gerrit Weimann, Ashraf Yassen
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 5, Pp 880-890 (2024)
Abstract Obstructive sleep apnea (OSA) is a sleep disorder which is linked to many health risks. The gold standard to evaluate OSA in clinical trials is the Apnea‐Hypopnea Index (AHI). However, it is time‐consuming, costly, and disregards aspects
Externí odkaz:
https://doaj.org/article/993b6e91571c4c6f8e3e4f8438d40464
Autor:
Peter N. Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Dirk Garmann
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1666-1686 (2023)
Abstract Copanlisib dose selection was established under the maximum tolerated dose paradigm, and no dedicated dose‐finding studies have investigated copanlisib dose selection when used in combination with rituximab. In CHRONOS‐3, copanlisib plus
Externí odkaz:
https://doaj.org/article/9de2185aad9e42999937070a78e87dc0
Autor:
Peter N. Morcos, Jan Schlender, Rolf Burghaus, Jonathan Moss, Adam Lloyd, Barrett H. Childs, Margaret E. Macy, Joel M. Reid, John Chung, Dirk Garmann
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 7, Pp 1197-1209 (2023)
Abstract Copanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confir
Externí odkaz:
https://doaj.org/article/8b78db85f6ae49dda69722b29cc9fdde
Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII
Autor:
João A. Abrantes, Alexander Solms, Dirk Garmann, Elisabet I. Nielsen, Siv Jönsson, Mats O. Karlsson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 894-903 (2019)
Bayesian forecasting for dose individualization of prophylactic factor VIII replacement therapy using pharmacokinetic samples is challenged by large interindividual variability in the bleeding risk. A pharmacokinetic‐repeated time‐to‐event mode
Externí odkaz:
https://doaj.org/article/fce18d99c0de4d1580bd6553bb3d5d03
Autor:
Alexander Solms, Matthias Frede, Scott D. Berkowitz, Anne Hermanowski‐Vosatka, Dagmar Kubitza, Wolfgang Mueck, Theodore E. Spiro, Stefan Willmann, Xiaoyu Yan, Liping Zhang, Dirk Garmann
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 805-814 (2019)
Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic (PK) data to
Externí odkaz:
https://doaj.org/article/3284b20cca0648198b411dd0ffa0f05c
Autor:
João A. Abrantes, Alexander Solms, Dirk Garmann, Elisabet I. Nielsen, Siv Jönsson, Mats O. Karlsson
Publikováno v:
Haematologica, Vol 105, Iss 5 (2020)
Pharmacokinetic-based prophylaxis of replacement factor VIII (FVIII) products has been encouraged in recent years, but the relationship between exposure (factor VIII activity) and response (bleeding frequency) remains unclear. The aim of this study w
Externí odkaz:
https://doaj.org/article/93cbc7eeffaa4384a6e7f705b3679541
Autor:
Liping Zhang, Xiaoyu Yan, Partha Nandy, Stefan Willmann, Keith A. A. Fox, Scott D. Berkowitz, Amarnath Sharma, Anne Hermanowski-Vosatka, Stephan Schmidt, Jeffrey I. Weitz, Dirk Garmann, Gary Peters
Publikováno v:
Therapeutic Advances in Cardiovascular Disease, Vol 13 (2019)
Background: This analysis aimed to evaluate the impact of rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome (ACS) and to determine whether therapeutic drug monitoring might provi
Externí odkaz:
https://doaj.org/article/85cc31f6651647ca9ef5a0fe39fba65c
Autor:
Jonathan Moss, Dirk Garmann, Rupert Austin, Florian Hiemeyer, Matthew J. Matasar, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Peter N. Morcos
Publikováno v:
Blood. 140:3629-3631
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::460077556e84544f792a462072cccb8d
https://doi.org/10.1182/blood-2022-162819
https://doi.org/10.1182/blood-2022-162819
Autor:
Dirk Garmann, Andrea Horvat-Broecker, Sebastiaan C. Goulooze, Joerg Lippert, Thomas Eissing, Meike Brinker, Nelleke Snelder, Amer Joseph, Andreas Seelmann
Publikováno v:
Clinical Pharmacokinetics. 61:451-462
Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3af0fc86ef3eea06673c4320212cb4ec
https://doi.org/10.1007/s40262-021-01083-1
https://doi.org/10.1007/s40262-021-01083-1